Journal Mobile Options
Table of Contents
Vol. 53, No. 3, 2010
Issue release date: April 2010
Section title: Original Paper
Intervirology 2010;53:146–153
(DOI:10.1159/000274975)

Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients

Lee S.a · Kim I.H.a · Kim S.H.a · Kim S.W.a · Lee S.O.a · Lee S.T.a · Kim D.G.a · Lee C.S.a · Choi C.S.b · Cho E.Y.b · Kim H.C.b
aDepartment of Internal Medicine, Research Institute for Medical Science, Chonbuk National University Medical School and Hospital, Jeonju, and bDepartment of Internal Medicine, Wonkwang University College of Medicine and Hospital, Iksan, South Korea
email Corresponding Author

In Hee Kim, MD

Department of Internal Medicine, Research Institute of Clinical Medicine

Chonbuk National University Medical School and Hospital

634-18 Keumam-dong, Dukjin-ku, Jeonju, Jeonbuk 561-712 (South Korea)

Tel. +82 63 250 1677, Fax +82 63 254 1609, E-Mail ihkimmd@chonbuk.ac.kr


References

  1. Lauer GM, Walker BD: Hepatitis C virus infection. N Engl J Med 2001;345:41–52.
  2. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C: review. Lancet 2003;362:2095–2100.
  3. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000;132:296–305.
  4. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–1374.
  5. Farrell GC: New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:607–610.
  6. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–982.
  7. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–965.
  8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM; PEGASYS International Study Group: Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–355.
  9. Harris JM, Martin NE, Modi M: Pegylation – a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001;40:539–551.
  10. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343:1666–1672.
  11. Foster GR: Pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther 2004;20:825–830.
  12. Glue P, Fang J, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Saif M, Jacobs S: Pegylated interferon-α2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556–567.
  13. Peginterferon-α2a Prescribing Information. Roche Laboratories, Inc., Nutley, NJ, USA.
  14. Peginterferon-α2b Prescribing Information. Schering-Plough Corp., Kenilworth, NJ, USA.
  15. Ascione A, De Luca M, Tartaglione MT, Lampasi F, Galeota Lanza A, Picciotto FP, Di Costanzo GG, Leandro G: Peginterferon-α2a plus ribavirin versus peginterferon-α2b plus ribavirin in naive patients with chronic hepatitis C virus infection: results of a prospective randomised trial. J Hepatol 2008;48(suppl 2):S370.

    External Resources

  16. Rumi M, Aghemo A, Prati GM, D’Ambrosio R, Donato MF, Russo A, Cerami N, Soffredini R, Colombo M: Randomized study comparing peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin in naive patients with chronic hepatitis C: final results of the Milan Safety Tolerability (MIST) study. Hepatology 2008;48(suppl 1):404A.
  17. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowaski MS; for the IDEAL Study Team: Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580–593.
  18. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J: Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645–652.
  19. Bruno R, Sacchi P, Ciappina V, Zochetti C, Patruno S, Maiocchi L, Filice G: Viral dynamics and pharmacokinetics of peginterferon-α2a and peginterferon-α2b in naive patients with chronic hepatitis C: a randomized, controlled study. Antiviral Ther 2004;9:491–497.
  20. Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C, Harvey J, Laughlin M: A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol 2006;45:204–213.